ClinicalTrials.gg
RecruitingNCT06776029Updated Oct 28, 2026

Fecal Microbiota Transplantation for Radiation-Induced Proctopathy

A Phase 2 interventional study of Fecal Microbiota Transplantation Capsule in Radiation Induced Proctitis, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this single-arm trial is to learn if Fecal Microbiota Transplantation (FMT) works to treat hemorrhagic radiation-induced proctopathy. The main questions it aims to answer are:

  • Dose FMT alleviate the symptom of severe rectal bleeding?
  • Dose FMT improve the endoscopic findings of proctopathy?

Participants will:

  • Take fecal microbiota capsules by 8 sessions over a 12-week period.
  • Visit the clinic once every 4 weeks for checkups and tests.
  • Keep a diary of their symptoms and the number of times they use other supportive care.
02

Conditions studied

  • Radiation Induced Proctitis

Keywords

  • fecal microbiota transplantation
  • rectal bleeding
  • radiation proctitis
03

In context

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

This study's planned enrollment of 20 is below the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.

Browse Gastrointestinal Hemorrhage studies →

Lead sponsor

Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 217 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-75 years old
  • At least 3 months since the completion of pelvic radiotherapy
  • No evidence of tumor recurrence or
  • Rectal bleeding with grade 2-4 by LENT-SOMA scales
  • Colonoscopy indicating rectal congested mucosa or telangiectasia
  • Poor response to supportive care, or level less than or equal to 70 g/L in the past 3 months

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic infectious diseases
  • Serious systemic diseases
  • Known allergies to any components of the study medication
  • Colonoscopy indicating rectal ulceration (>1cm2), fistula, stricture, or necrosis
  • Late complications related to pelvic radiation injury
  • Other hemorrhagic or coagulation disorders
  • Previous rectal resection
  • Bowel obstruction or perforation that require surgery
  • Cognitive or psychological disorder
  • to FMT administration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Fecal Microbiota Transplantation

    Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.

    Biological: Fecal Microbiota Transplantation Capsule

Interventions

  • FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.

06

What researchers measure

Primary outcomes

  1. Number of participants with mild rectal bleeding (grade 0-1)

    The symptom of rectal bleeding will be assessed by LENT-SOMA scales

    Time frame: At the time of 12 weeks since the start of treatment

Secondary outcomes

  1. Number of participants with mild rectal bleeding (grade 0-1)

    The symptom of rectal bleeding will be assessed by LENT-SOMA scales

    Time frame: At the time of 24 weeks since the start of treatment

  2. Number of participants with improved colonoscopic findings

    The colonoscopic findings will be assessed by the Vienna Rectoscopy Score.

    Time frame: At the time of 12 and 24 weeks since the start of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Primary completion
Mar 31, 2026→Mar 31, 2027
Oct 28, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Mar 31, 2026→Mar 31, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06776029
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Feb 1, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Qiyuan Qin, M.D.
Contact
qinqy3@mail.sysu.edu.cn
86-20-38254052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fecal Microbiota Transplantation Capsule

Start the discussion